Siemens Healthineers Forum on COVID-19 TestingLeading the Way to Normalcy
Siemens Healthineers Forum on COVID-19 Testing
Changing COVID-19 testing demands require clinical laboratories to keep up with an increasing number of patients, samples, and variants. Siemens Healthineers provides the flexibility you want for the clinical results you need with innovative, COVID-19 testing solutions.
at the Siemens Healthineers Forum, explore our COVID-19 testing portfolio, from a highly sensitive
RT-PCR test to high throughput or point of care antigen and antibody assays.
At the Forum on COVID-19 Testing, you will learn how Siemens Healthineers is shaping the future of healthcare, so you can drive better outcomes.
From the lab to the point of care, Siemens Healthineers offers a full portfolio of COVID-19 testing solutions that consistently delivers sensitivity and performance—to get us to what’s next.
Large-scale Testing and Diagnosis
High-throughput Lab Antigen Testing
Molecular PCR Testing
Gold standard for accurate and early detection of infection.
Near-patient testing can be used to identify and isolate infected people more quickly.
Point-of-care Rapid Antigen Testing
Rapid antigen testing can help communities get ahead of the spread.
Management and Monitoring
Management and monitoring are critical in determining the full scope of the disease, combating the pandemic, and rebuilding public conﬁdence.
High-throughput Lab Antibody Testing
Highly accurate for detection and monitoring of immune response through infection and in vaccination.
Point-of-care Antibody Testing
Our Booth at ESCV
How can your laboratory deliver more impactful results for the detection and management of COVID-19?
Explore Siemens Healthineers full portfolio of COVID-19 testing solutions that consistently delivers sensitivity and performance—to get us to what’s next on the path to normalcy.
ESCV Symposium: SARS-CoV-2: from viral detection to variant identification
9:00-10:00 CET (8:00-9:00 BST)
Dr. Guido Hennig: Scientific Affairs at Siemens Healthineers
Alexandre Gilles: SARS-CoV-2 detection: from assay design to variant surveillance, R&D Scientist at Fast Track Diagnostics, a Siemens Healthineers company
Dr. Onur Bilenoglu: SARS-CoV-2 variant identification: how to keep up with mutations? R&D Manager at A1 Lifesciences, Istanbul, TurkeyProf. Zeynep Ceren Karahan: Laboratory experience on SARS-CoV-2 mutation detection. Ankara University School of Medicine, Department of Medical Microbiology & Ankara University School of Medicine, Ibn-i Sina Hospital, Central Microbiology Laboratory
Distributed by Siemens Healthineers. CLINITEST Rapid COVID-19 Antigen Test: Not available for sale in the U.S.
This test has not been reviewed by the FDA. In the U.S., use of this test is limited to laboratories that are certiﬁed under Clinical Laboratory Improvement Amendments of 1988 (CLIA) to perform high-complexity testing.
The SARS-CoV-2 molecular and antibody tests have not been FDA-cleared or approved. These tests have been authorized by FDA under an EUA for use by authorized laboratories. The molecular test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. The antibody test has been authorized only for detecting the presence of antibodies against SARS-CoV-2, not for any other viruses or pathogens. These tests are only authorized. for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the. authorization is terminated or revoked sooner. Product availability may vary from country to country and is subject to varying regulatory requirements.